Table 3 Risk factors for MetS after pediatric HSCT.
Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Risk of MetS, OR (95% CI) | P value | Risk of MetS, OR (95% CI) | P value | |
Protein (gram) | 1.00 (0.98–1.01) | 0.96 | - | |
Protein (E%) | 0.88 (0.75–1.02) | 0.12 | - | - |
Carbohydrate (gram) | 1.00 (0.99–1.01) | 0.38 | - | |
Carbohydrate (E%) | 0.97 (0.91–1.04) | 0.39 | - | - |
Fat (gram) | 1.03 (1.00–1.05) | 0.016 | - | |
Fat (E%) | 1.13 (1.03–1.26) | 0.016 | 1.20 (1.06–1.39) | 0.008 |
Saturated fat (gram) | 1.05 (1.00–1.09) | 0.047 | - | |
Saturated fat (E%) | 1.14 (0.98–1.34) | 0.08 | - | |
Monounsaturated fat (gram) | 1.04 (0.99–1.09) | 0.12 | - | |
Monounsaturated fat (E%) | 1.05 (0.92–1.19) | 0.43 | - | |
Polyunsaturated fat (gram) | 1.04 (0.92–1.19) | 0.51 | - | |
Polyunsaturated fat (E%) | 0.94 (0.70–1.23) | 0.68 | - | |
Sex (male) | 3.32 (1.22–10.74) | 0.015 | 1.73 (1.01–1.20) | 0.02 |
Age at follow up (years) | 1.12 (1.06–1.20) | 0.0002 | 1.09 (1.01–1.20) | 0.04 |
Age at transplantation (years) | 1.09 (0.09–1.22) | 0.14 | - | - |
Time from transplantation (years) | 1.11 (1.04–1.19) | 0.0015 | - | |
Donor age | 1.03 (0.99–1.07) | 0.19 | - | - |
Treatment groups | ||||
Chemotherapy-based conditioning | Reference | - | ||
TBI-based conditioning | 44.3 (6.8–961.3) | <0.0001 | 32.42 (4.87–665.1) | 0.002 |
Acute GvHD | ||||
No acute GvHD | Reference | - | - | - |
Acute GvHD | 2.1 (0.7–6.8) | 0.2 | - | - |
Chronic GvHD | ||||
No chronic GvHD | Reference | - | - | - |
Chronic GvHD | 0.8 (0.2–2.6) | 0.8 | - | - |
Diagnosis | ||||
Nonmalignant disease | Reference | - | - | - |
Malignant disease | 16.6 (2.6–357.8) | 0.0005 | - | - |
Donor match- | ||||
HLA-identical sibling | Reference | - | - | - |
Other donors | 1.5 (0.6–4.3) | 0.5 | - | - |
